Background: Long-term seroprotection data are essential for decision-making on the need
with the development and the publishing of the present manuscript. All authors had full access to the data and had final responsibility to submit for publication. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Amongst older children and adults, seroprevalence is in general extremely high in lowincome regions such as sub-Saharan Africa and very low in high-income regions such as Western Europe and North America, but increases have been observed between 1990 and 2005 [1] . Improved standards of sanitation and water supply in lower-income regions have decreased transmission of HAV. With less HAV circulating within populations, the average age of infection is driven upwards. This can have the paradoxical effect of increasing HAVrelated mortality and morbidity, because disease severity is strongly age dependent, with adults far more likely to develop clinical illness [2, 3] . Therefore HAV vaccination may play a key role in preventing increases in HAV-related disease in regions with changing patterns of HAV transmission.
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Both inactivated and live attenuated HAV vaccines have been developed. Both these vaccine types are highly immunogenic and immunization will generate long-lasting, possibly lifelong, protection against hepatitis A in children as well as in adults [4] . There do not yet exist clinical trials of HAV vaccines of sufficiently long duration to empirically demonstrate lifelong persistence of anti-HAV antibodies, although longer-term data are beginning to become available [5, 6] . Therefore many studies have attempted to estimate long-term persistence based on short-term data using various modeling methods for hepatitis A [7] [8] [9] and for other vaccine preventable infections including diphtheria, [10, 11] hepatitis B, [12] meningitis A, [13] pertussis, [14] Japanese encephalitis, [15] , and HPV, [16] in order to address duration of vaccine protection. Such models generally employed either exponential-type or linear Manuscript   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 modelling approaches according to whether antibody titres were in natural units or logtransformed. While earlier models estimated antibody persistence at a population level, there has been a trend toward individual-level modeling in more recent publications.
Argentina has been classified as being of intermediate-level HAV endemicity [1] , but there is evidence of decreasing seroprevalence among younger age groups in the last 15 years [17, 18] . Long-term anti-hepatitis A virus antibody persistence has been examined in Argentinean children 10 years after the initial study in which they received two doses of inactivated hepatitis A vaccine (Avaxim® 80U Pediatric, Sanofi Pasteur, Lyon, France) [19, 20] . In the 10-year follow-up study we found that the vaccine conferred long-term protection amongst children who were seronegative prior to vaccination.
Data are now available for this cohort up to 14-15 years post first HAV vaccination (primary vaccination of two-dose protocol). We have used these new data to investigate by extrapolation the long-term anti-HAV antibody persistence for: a) the mean duration of seroprotection from HAV infection conferred by the Avaxim® 80U Pediatric vaccine; and b) the percentage of seropositive vaccinees at 20, 25 and 30 years post vaccination. We have employed a range of statistical models to investigate the models which most appropriately fit the anti-HAV antibody persistence data.
MATERIALS AND METHODS

Trial Design and Study Population
Of 537 healthy Argentinean children aged 12 months to 15 years enrolled between December 1996 and January 1997 from a single study centre (Hospital de Niños "Dr. Ricardo Gutiérrez", Buenos Aires, Argentina) in an open, non-controlled trial of inactivated Avaxim®   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 80U Pediatric vaccine (Sanofi Pasteur, Lyon, France), 54 children aged 12 to 60 months were invited for serum anti-HAV measurements at 10 years post first vaccine dose, from May to November 2007 (89% seronegative pre-vaccination) (Figure 1 ). The full vaccination course administered in 1996-7 consisted of two doses administered six months apart. Only subjects completing the course were selected for follow-up. Of this cohort, 33 were additionally followed at 14-15 years post first dose (91% seronegative pre-vaccination), between December 2010 and February 2012. Pre-defined exclusion criteria were: 1) having received an additional booster dose of hepatitis A vaccine after the second dose; 2) having had moderate or severe illness (such as varicella) or immunodeficiency; and 3) having had previous treatment with growth hormone or human immunoglobulins or having received whole blood cells or blood product transfusion during the previous six months. This was to ensure blood samples collected would provide reliable measures of anti-HAV concentrations.
However, no subject was excluded from taking part in the study based on any of these criteria. The trial protocol was approved by the internal review board and ethics committee of the Hospital de Niños "Dr. Ricardo Gutiérrez". Further information on the cohort has been previously published [19, 20] .
One patient with anti-HAV concentration measurements from all six time points was missing date of follow-up for the 2 week (post-first dose visit), 6 month (pre-booster) and 6.5 month (post-booster) time points. These dates were imputed using the median time to each of these visits for the rest of the cohort.
Laboratory Tests
Serum anti-HAV antibody concentrations were measured by VIDAS Anti-HAV Total (HAVT, BioMerieux, France). The assay combines a two-step enzyme immunoassay competition method with fluorescent detection (ELFA) [21] . Results are expressed in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 mIU/mL (WHO reference standard first Reference Preparation Hepatitis A Immunoglobulin [100 mIU/mL]). Sera with anti-HAV ≥20 mIU/mL (lower limit of quantification, LLOQ) were considered seropositive. At the time of current study the serological test-system used in the initial study (antibody concentrations had been assessed using commercial radioimmunoassay [HAVAB, Abbot Laboratories, North Chicago] modified to increase the sensitivity) was not available [21] .
Statistical Analysis
We investigated different approaches used previously to analyze antibody persistence following vaccination [9, 10, 12, 14-16, 18, 22-27] , in order to identify the most appropriate and best fitting models for our dataset. Previous analyses of anti-HAV decline post vaccination have employed extrapolation methods assuming exponential decay [7] [8] [9] and so we have investigated this approach (Models 1 and 2). There is also a large body of literature on antibody decay which adopts mixed effects models for similarly shaped antibody decay curves. Mixed effects models contain both fixed and random effects, which are particularly appropriate for fitting to such longitudinal data and allowing for the dependence of withinchild measurements [28, 29] . We have therefore employed mixed effects models as the underlying structure of all other models evaluated (Models 3 to 8). We additionally investigated the impact of adding the covariates age, gender and anti-HAV serostatus at enrolment to these models. Models 1 and 2 are extrapolations based on methods previously used to estimate duration of seroprotection of hepatitis A vaccines [7] [8] [9] . Model 1 extrapolates using geometric mean concentrations (GMCs) taken at peak concentration (post-booster) and 14-15 years post vaccination and assumes exponential decay of log 10 antibody over time, so , log 10 antibody at time t, is defined as: 
where c can be up to 4 (i.e., models can include quadratic, cubic and up to power 4 terms of the time covariate).
Model 5 is a segmented linear mixed effects model which contains fixed and random effects for both slope and intercept parameters (as for Model 3) but additionally allows fitting to antibody concentration measurements from all six time points:
where is an indicator: =1 for time up to six months (i.e. up to peak antibody concentration) and =0 for time post six months period of antibody decline. Model 6 is similarly segmented but additionally involves exponent parameters (c) as described for Model 4. We fitted a linear model for the antibody increase phase i.e. up to 6 months followup, then an exponential model for the antibody decline phase (post six months). 
RESULTS
Cohort characteristics
Between December 2010 and February 2012, 33 children were followed up at 14-15 years post first vaccination. The remaining 21 children of the cohort were followed up at 10 years only, May to November 2007 and then lost to follow-up ( Figure 1 ). Of these 54 children with long-term follow-up, 27 (50%) were male; mean age at enrolment was 30.4 months (standard deviation [SD] 12.5, range 11.6-59.9 months). There was no statistically significant difference in age between seropositives and seronegatives (27.6 months [SD 19.9] and 30.7 months [SD 11.6], respectively (p=0.717). Two subjects who were followed to 14-15 years and were seronegative pre first vaccination reported receiving immunosuppressive therapy during the preceding six months: one received aerosol prophylaxis for asthma twice weekly (Simbicort™), while the other received Flutivent™, one puff daily, also aerosol asthma prophylaxis. However, as asthma prophylaxis was not considered to prevent the development of vaccine-induced anti-HAV antibodies, these subjects were not excluded from analyses. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 This is consistent with summary of product characteristics which show that immune system disorders reported with these products are uncommon to rare. [37, 38] Antibody concentrations over time Table 1 provides parameter estimates and fit statistics for each modeling approach. Models 1 and 2 gave a reasonable fit to the observed data using eyeball assessment but no formal evaluation of fit was possible because the AIC and BIC statistics could not be calculated. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 inclusion of anti-HAV serostatus prior to vaccination did, resulting for some models, in a coefficient which was statistically significant (data not shown). Therefore serostatus was retained in the models but age and gender were dropped from the final model selected for each model type.
Model selection
Model 3 using all three time points of antibody decline (post-booster, 10 and 14-15 years) demonstrated a statistically significant yearly decrease in antibody concentration of 0.117 log 10 mIU/mL per year (p<0.001, Table 1 ). Restricting Model 3 to using the 10 year and 14- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 improve model fit and these terms were not statistically significant (cubic model AIC 90, BIC 116, Table 1 ; results for fourth order model not shown). Table   1 ) and decreasing trend post-booster (-1.94 mIU/mL/year p<0.001). However, the AIC and BIC values suggest a poor model fit to the data. This is due to the high variability of prebooster concentrations (Figure 2 ) and the necessary inclusion of more covariates in the model (which determine the segmented structure).
Model 6, involving a quadratic time since vaccination term for the antibody decline segment only, provided a better fit to the data and all covariates remained significant (Table 1) .
Models 7 and 8, fitting to the anti-HAV decline phase but including initial rate of anti-HAV increase as a covariate, did not meaningfully improve fit to data above that of models using the decline phase data only (Models 3 and 4).
Quadratic models appear to better capture the decreasing trend of log 10 antibody concentration, but the quadratic terms in Models 4, 6 and 8 are all positive ( year data) showed a slight increase in anti-HAV concentrations. Table 2 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 trend, which is the most relevant phase for prediction of antibody persistence, and also in the adoption of fixed and random effects [14, 15] . However, this model additionally includes data from the early phase of antibody rise post first-dose, thus maximizing utilization of the dataset.
The best fitting models in terms of AIC and BIC goodness of fit statistics included quadratic
terms, but such models fail for long-term projections in terms of biological plausibility, because we would not expect anti-HAV concentrations to increase over time (in the absence of natural boosting). In their discussion of the appropriate modeling approach, Bailleux et al state that in general, non-linear approaches are applicable to the full follow-up period whereas a linear approach is, "appropriate applied to the period after the initial rapid decay phase stabilizes" [14] . In the absence of additional follow-up time points between the peak post-booster measure and 10 years' follow-up, it was most appropriate to focus on fit to the plateau phase rather than model the full period of antibody decline, as we had sparse data in the rapid decay phase. The segmented models allow full use of the dataset, by incorporating information from early time points as well as those from the anti-HAV decline period.
Our analysis predicts that the seroprotection rate after two doses of Avaxim® 80U Pediatric vaccine remains high (88%) for at least 30 years after first vaccination. A full vaccination course consisting of two vaccine doses confers long-term immunity from HAV infection by the induction of persistent vaccine-induced anti-HAV antibodies.
Age at vaccination and gender were not found to be significantly associated with pattern of antibody decline, but serostatus prior to vaccination was significant. Children who were anti-HAV seropositive before first hepatitis A vaccination exhibited slower rates of antibody decline and are predicted to remain seropositive to at least 30 years post vaccination. These   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 children may have natural hepatitis A infection-mediated in addition to vaccine-mediated immunity.
This study is one of the longest duration follow-ups post hepatitis A vaccination in children.
Van Herck et al have reported the 17 year follow-up of health adults after two dose inactivated hepatitis A vaccine [5] . Raczniak et al recently reported anti-HAV levels amongst subjects who were vaccinated with inactivated hepatitis A vaccine as children, 17 years previously [40] , but this was a cross-sectional study of a convenience sample. Thus to our knowledge, the current study is the longest prospective study of children post hepatitis A vaccination.
There are some limitations to this study. With no antibody concentration measurements between the post-booster sample (at 6 months post baseline) until the 10 year measurement, we cannot estimate the change point at which the phase of rapid antibody decline ends and the slower decay phase begins. In the absence of sufficient data to estimate this point, the segmented models have used the point of peak antibody concentration (post-booster measure) and 10 year follow-up point as change points, but it is more likely that the second change point, the point at which rapid antibody decline is replaced by a more stable phase, is around 6-12 months post-booster, as has been observed in other antibody persistence studies [15, 33, 41] . Another important limitation is the relatively small sample size which decreases further with increasing follow-up. Two subjects received immunosuppressive therapy at the 14-15 year time point (aerosol asthma prophylaxis). However, as noted previously these subjects were not excluded from analyses which benefited sample size. Exclusion of these subjects would have further diminished the limited sample size at this time point (n=33).
Our predictions required us to extrapolate data beyond the 14-15 year period of observation, which implicitly assumes that the linear rate of antibody decay must continue to the time 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 horizon of our prediction. Indeed a few subjects did demonstrate an increase in the anti-HAV concentration between 10 and 14-15 years counter to the trend in the majority of subjects, possibly due to natural exposure to HAV. However, based on our model comparisons, the linear assumption would appear justified and is consistent with antibody persistence studies for other diseases. [10, 14, 15] However, any extrapolation of statistical models outside the period of observation should be interpreted with caution.
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2 No confidence or credible interval produced using Model 1.
3 Geometric mean and 95% confidence interval used for Model 2 for comparability with Model 1.
4 AIC and BIC goodness of fit statistics cannot be calculated for Models 1 and 2. 
